Connexion
Identifiant
Mot de passe
Retenir
Codes oubliés ?
Devenir membre gratuitement
Inscription
Inscription
Devenir membre
Inscription gratuite
Devenir client
Découvrez nos services
Paramètres
Paramètres
Cotations dynamiques 

Accueil Zonebourse  >  Actions  >  Nasdaq  >  Dendreon Corporation    

SynthèseGraphiquesActualitésAnalysesAgendaSociétéFinancesConsensusRévisionsFondsCommunauté 
Métier
Discovers, develops and commercializes novel products for the treatment of cancer

Dendreon Corp. is a biotechnology company, which focuses on discovery, development and commercialization of novel therapeutics that improves cancer treatment options for patients.

The company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy ACI product candidates designed to stimulate an immune response in a variety of tumor types.

It is an exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers.

Dendreon was founded by Edgar G. Engleman and Samuel Strober in 1992 and is headquartered in Seattle, WA.

Nombre d'employés : 755 personnes.
Ventes par activité
20122013Delta
USD (en Millions)%USD (en Millions)%
Novel Therapeutics325,53100%283,75100% -14.73%
Ventes par région
20122013Delta
USD (en Millions)%USD (en Millions)%
United States325,53100%283,75100% -14.73%
Dirigeants
Nom AgeDepuisTitre
Craig R. Jalbert532015President, Secretary, Treasurer & Director
William Monteith562009Executive Vice President-Technical Operations
Andrew S. Sandler, MD492014Chief Medical Officer & Executive Vice President
April Falcone--Head-Corporate Communications
Silvio Pacheco, MBA--Chief Customer Officer
Karen Brophy512012Vice President & Head-Human Resources
Actionnaires
Nom Actions%
John H. Johnson 1 704 624 1,07%
Norges Bank Investment Management 1 155 138 0,73%
David L. Urdal, PhD 644 750 0,41%
Mark W. Frohlich, MD 525 283 0,33%
Gregory T. Schiffman MBA, CPA 459 880 0,29%
Christine Mikail Cvijic 351 465 0,22%
Gregory R. Cox, CPA 327 754 0,21%
William Monteith 209 875 0,13%
Andrew S. Sandler, MD 207 914 0,13%
Joseph I. DePinto, MBA 136 694 0,086%
Secteur
Santé
Recherche pharmaceutique et médicale
 Recherche biotechnologique et médicale
  Recherche biotechnologique et médicale
   Recherche biotechnologique et médicale - NCA
Publicité
Secteur Recherche biotechnologique et médicale
CroissanceRentabilité
INCYTE CORPORATIO..
ALNYLAM PHARMACEU..
ALKERMES PLC
QUINTILES TRANSNA..
UNITED THERAPEUTI..
CELLTRION, INC.
INTREXON CORP
QIAGEN NV
ANACOR PHARMACEUT..
ISIS PHARMACEUTIC..
SEATTLE GENETICS,..
ICON PLC
ACADIA PHARMACEUT..
BIO-TECHNE CORP
BB BIOTECH AG
PAREXEL INTERNATI..
CHARLES RIVER LAB..
NOVAVAX, INC.
WUXI PHARMATECH (..
PUMA BIOTECHNOLOG..
-
Secteur Recherche biotechnologique et médicale
Dendreon Corporation : Connexions
Matritech, Inc.
Coordonnées société
Dendreon Corp.
1301 2nd Avenue
Suite 3200
Seattle, WA 98101

Phone : +1.206.256.4545
Fax : +1.206.256.0571
Web : www.dendreon.com
© 2015 People , Fundamentals and Ownership